ANTIPODES PARTNERS Ltd Boosts Stock Position in HCA Healthcare, Inc. (NYSE:HCA)

ANTIPODES PARTNERS Ltd increased its holdings in HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 1,415.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 435,423 shares of the company's stock after buying an additional 406,682 shares during the period. HCA Healthcare comprises approximately 4.7% of ANTIPODES PARTNERS Ltd's holdings, making the stock its 7th biggest position. ANTIPODES PARTNERS Ltd owned 0.18% of HCA Healthcare worth $150,472,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Norges Bank bought a new position in shares of HCA Healthcare in the fourth quarter valued at approximately $840,286,000. GAMMA Investing LLC boosted its holdings in shares of HCA Healthcare by 40,527.3% in the first quarter. GAMMA Investing LLC now owns 1,703,907 shares of the company's stock valued at $5,887,850,000 after acquiring an additional 1,699,713 shares in the last quarter. Barclays PLC raised its holdings in shares of HCA Healthcare by 85.7% in the 4th quarter. Barclays PLC now owns 1,061,891 shares of the company's stock worth $318,727,000 after purchasing an additional 489,916 shares in the last quarter. Two Sigma Investments LP boosted its stake in shares of HCA Healthcare by 12,016.0% during the 4th quarter. Two Sigma Investments LP now owns 467,437 shares of the company's stock worth $140,301,000 after acquiring an additional 463,579 shares in the last quarter. Finally, Metropolis Capital Ltd purchased a new stake in HCA Healthcare during the first quarter valued at about $117,984,000. 62.73% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have weighed in on HCA shares. Robert W. Baird reiterated a "neutral" rating and set a $336.00 price objective (down from $396.00) on shares of HCA Healthcare in a research report on Tuesday, April 15th. Baird R W downgraded shares of HCA Healthcare from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, April 15th. Morgan Stanley set a $410.00 price objective on shares of HCA Healthcare and gave the company an "equal weight" rating in a research note on Monday, June 9th. Bank of America lowered shares of HCA Healthcare from a "buy" rating to a "neutral" rating and set a $394.00 price objective on the stock. in a research note on Wednesday, July 16th. Finally, Truist Financial lifted their price objective on shares of HCA Healthcare from $390.00 to $415.00 and gave the company a "buy" rating in a research note on Wednesday, July 16th. Eight analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $399.46.

HCA Healthcare Price Performance

NYSE HCA traded down $7.22 on Friday, reaching $334.26. The company's stock had a trading volume of 3,175,863 shares, compared to its average volume of 1,334,458. HCA Healthcare, Inc. has a 52 week low of $289.98 and a 52 week high of $417.14. The company has a current ratio of 1.19, a quick ratio of 1.06 and a debt-to-equity ratio of 69.07. The firm has a market cap of $80.41 billion, a PE ratio of 14.86, a price-to-earnings-growth ratio of 1.19 and a beta of 1.47. The business has a 50-day moving average price of $373.81 and a 200 day moving average price of $345.68.

HCA Healthcare (NYSE:HCA - Get Free Report) last posted its quarterly earnings results on Friday, July 25th. The company reported $6.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.20 by $0.64. HCA Healthcare had a net margin of 8.07% and a return on equity of 1,063.91%. The firm had revenue of $18.61 billion during the quarter, compared to analyst estimates of $18.49 billion. During the same quarter in the prior year, the business posted $5.50 earnings per share. The company's quarterly revenue was up 6.4% compared to the same quarter last year. Sell-side analysts expect that HCA Healthcare, Inc. will post 24.98 EPS for the current year.

HCA Healthcare Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Tuesday, September 16th will be given a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 0.86%. HCA Healthcare's payout ratio is 12.81%.

Insider Buying and Selling

In other news, COO Jon M. Foster sold 15,698 shares of the firm's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $369.32, for a total value of $5,797,585.36. Following the transaction, the chief operating officer owned 12,646 shares of the company's stock, valued at approximately $4,670,420.72. This trade represents a 55.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.30% of the company's stock.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.